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Introduction {#sec005}
============

Hypertension is an important public health issue worldwide \[[@pone.0125275.ref001]\] Hypertension could damage various target organs \[[@pone.0125275.ref002]\] and thus raise the risks of coronary heart disease, heart failure, chronic kidney disease (CKD) and stroke \[[@pone.0125275.ref003]--[@pone.0125275.ref005]\]. Left ventricle hypertrophy (LVH) is a common subclinical organ damage induced by hypertension. The prevalence of LVH among hypertensive patients is about 20%--40% \[[@pone.0125275.ref006]\]. LVH has been suggested as a validated marker indicating the mortality of cardiovascular diseases (CVDs) \[[@pone.0125275.ref007]\]. Therefore, identifying specific risk factors of LVH in hypertensive patients is quite important for reducing the incidence of cardiovascular events. Many common risk factors of LVH have been confirmed through epidemiologic research, such as obesity, old age, high blood pressure, and smoking status \[[@pone.0125275.ref008]\].

Now, growing attention has been paid to some serological indices, such as serum bilirubin level. As the final product of heme catabolism, bilirubin is anti-inflammatory and antioxidant in vitro and in vivo \[[@pone.0125275.ref009]\]. Epidemiologic evidence has shown that the increase in serum bilirubin level, even within normal range \[[@pone.0125275.ref010]\], is a protective factor of CVDs. A clinical study suggests that people with lower serum bilirubin levels are more likely to suffer from hypertension, diabetes and obesity \[[@pone.0125275.ref011]\]. Moreover, prospective studies also show that low bilirubin level is a main predictive factor of cardiovascular events, such as stroke, heart failure and coronary artery disease \[[@pone.0125275.ref012]--[@pone.0125275.ref014]\]. However, the possible association between serum bilirubin level and the occurrence of LVH in essential hypertensive patients has been rarely investigated. Bilirubin can suppress the oxidation of blood lipids including low-density lipoprotein (LDL), and the application of bilirubin can improve the marker of anti-oxidative stress \[[@pone.0125275.ref015], [@pone.0125275.ref016]\]. Therefore, we assume that high serum bilirubin level may be a protective factor of LVH in hypertensive patients. On this basis, serum bilirubin level examination can be conducted as a cheap routine test and as a potential predictor of LVH in newly-diagnosed hypertensive patients. The aim of the present study is to evaluate the relation between serum bilirubin level and the occurrence of LVH in newly-diagnosed hypertensive patients.

Methods {#sec006}
=======

Study population {#sec007}
----------------

This cross-sectional study preliminarily involved 408 consecutive hypertensive patients who had not received any treatment before and were enrolled in the outpatient clinic of the Third Affiliated Hospital at Southern Medical University between October 2013 and July 2014. All patients then underwent physical and Laboratory examinations. The inclusion criteria were as follows: no history of myocardial infarction, heart failure, cardiac valve disease, severe renal function impairment \[defined by an estimated glomerular filtration rate (eGFR) \<60 ml/min/1.73 m^2^\], coronary bypass surgery or angioplasty, diabetes mellitus or renal insufficiency; no treatment with urate-lowering medication (allopurinol and probenecid); no secondary or malignant hypertension. Sixty-two patients who did not meet the above criteria were excluded. Therefore, 344 hypertensive patients were involved the final statistical analysis ([S1 Dataset](#pone.0125275.s001){ref-type="supplementary-material"}). The study protocol was approved by the Ethics Committee of Southern Medical University, and written informed consent was obtained from all participants.

Blood pressure measurements {#sec008}
---------------------------

Newly diagnosed hypertension was defined as systolic blood pressure (SBP) ≥ 140 mmHg and (or) diastolic blood pressure (DBP) ≥ 90 mmHg. Blood pressures were measured using a mercury sphygmomanometer. Three measurements were taken at a 10-min interval and then averaged to define the clinic SBP or DBP.

Laboratory examinations {#sec009}
-----------------------

Serum total bilirubin, direct bilirubin, and indirect bilirubin levels were measured by the vanadate oxidation method using automatic biochemical analyzer. Hematologic test was measured using an automated hematology analyzer (Bayer Diagnostics, Newbury, and Berkshire, UK). During blood routine test \[red blood cell (RBC) count, white blood cell (WBC) count, platelet count, hemoglobin, mean corpuscular volume and red cell distribution width (RDW)\], fasting blood glucose, and creatinine, as well as the fasting serum lipid status including levels of total cholesterol (TC), LDL-cholesterol, high-density lipoprotein (HDL)- cholesterol, triglyceride (TG), and C-reactive protein (CRP) were recorded. Height and weight were measured, and the body mass index (BMI) was calculated as weight (kg) divided by height squared (m2). The eGFR was calculated as follows \[[@pone.0125275.ref017]\]: 186×SCr-1.154×age in years-0.203×1.210 (if black) ×0.742(if female) 36. Then CKD was defined as eGFR \<60 ml/min/1.73 m^2^.

Echocardiography {#sec010}
----------------

All echocardiographic tests were performed on each subject with a commercially available machine (Fair Medical Company Ltd, Matsudo, Japan) using a 2.5 Hz transducer. The overall single-dimensional left ventricular measurements and the two-dimensional views were obtained according to the American Society of Echocardiography standard \[[@pone.0125275.ref018], [@pone.0125275.ref019]\]. Left ventricular mass (LVM) was calculated as follows \[[@pone.0125275.ref020]\]: LVM = 1.04×0.8×{(VST~d~ × LVID~d~ × PWT~d~) 3-(LVID~d~) 3} +0.6, where IVS~d~ is diastolic interventricular septum, LVD~d~ is diastolic left ventricular dimension, and PWT~d~ is diastolic posterior wall thickness. The left ventricle mass index (LVMI) was computed as = LVM/BSA (Body Surface Area, BSA). LVH was defined as: LVMI ≥ 125 g/m2 for men and ≥ 110 g/m2 for women \[[@pone.0125275.ref021]\].

Statistical analysis {#sec011}
--------------------

The study patients were divided into an LVH group (n = 206) and a non-LVH group (138). Data were reported as mean ± standard deviation for quantitative variables and as percentages for qualitative variables. Whether a continuous variable was in normal distribution was assessed using the Kolmogorov---Smirnov test. Differences between groups were tested by Student t-test for continuous variables and by Chi-square test for categorical variables. Correlations between LVMI and other variables were calculated by Pearson's or Spearman's test as appropriate. The significant determinants for LVMI were detected with stepwise multiple linear regression, and the odds ratios (ORs) of independent variables were computed with stepwise multiple logistic regression. Collinear diagnostics within variables was applied before the regression modeling. Statistical analysis was performed on SPSS 19.0 (SPSS Inc, USA) with the significance level at P\<0.05.

Results {#sec012}
=======

General information of the subjects {#sec013}
-----------------------------------

[Table 1](#pone.0125275.t001){ref-type="table"} summarizes the demographic and clinical data of the two groups. The average ages of the two groups are 47.8±7.9 and 47.2±7.6 years old, respectively (P = 0.481). The sex ratios are not significantly different between groups. Total bilirubin and indirect bilirubin levels are both significantly lower in the LVH group than in the non-LVH group. Besides, the LVH group tends to be smokers and have higher SBP, DBP, glucose level, serum creatinine, uric acid, metabolic components, and RDW. Echocardiography shows that many indicators from the LVH group are significantly higher compared the non-LVH group. Other variables are all not different between the two groups ([Table 1](#pone.0125275.t001){ref-type="table"}).

10.1371/journal.pone.0125275.t001

###### Clinical characteristics of hypertension patients with and without LVH.

![](pone.0125275.t001){#pone.0125275.t001g}

  Parameters                          Non-LVH group   LVH group    *P*
  ----------------------------------- --------------- ------------ -------
  Age, y                              47.8±7.9        47.2±7.6     0.481
  Sex(male)                           118(57.3%)      89(64.5%)    0.181
  Smoking, yes                        27(13.1%)       46(33.3%)    0.000
  Body mass index, kg/m^2^            26.7±3.7        26.4±3.2     0.482
  SBP, mmHg                           150.6±10.0      155.4±13.3   0.000
  DBP, mmHg                           99.0±8.1        101.3±10.0   0.022
  Triglyceride, mmol/dL L             1.8±0.5         1.9±0.5      0.515
  HDL-cholesterol, mmol/dL            1.1±0.2         1.1±0.2      0.289
  LDL- cholesterol, mmol/dL           3.2±0.8         3.1±0.8      0.926
  Total cholesterol, mmol/dL          5.1±0.9         5.1±0.8      0.995
  Glucose, mmol/dL                    5.6±0.6         5.7±0.6      0.040
  eGFR,mL/min/1.73                    109.5±29.2      104.4±22.9   0.072
  Serum creatine, mmol/dL             67.3±13.2       71.0±13.2    0.010
  Uric acid, μmol/L                   343.5±49.9      370.4±46.7   0.000
  Hs-CRP, mg/dL                       2.3±5.4         2.5±4.1      0.750
  Alanine aminotransferase, U/L       32.2±27.7       29.5±19.5    0.325
  Aspartate aminotransferase, U/L     25.1±10.3       25.1±12.0    0.968
  Blood urea nitrogen, mmol/L         4.7±1.1         4.9±1.2      0.257
  Metabolic components,n              1.6±1.0         1.8±1.1      0.145
  Total bilibin, μmol/L               14.0±4.5        11.4±4.1     0.000
  Direct bilirubin, μmol/L            3.2±2.4         3.1±2.6      0.999
  Indirect bilirubin, μmol/L          10.8±4.5        8.2±4.2      0.000
  White blood cell, ×10^12^/L         6.2±1.9         6.1±1.6      0.760
  Red blood cell, ×10^12^/L           4.7±0.3         4.8±0.2      0.465
  Red cell distribution width (%)     12.7±0.7        12.9±0.9     0.014
  Hemoglobin,g/L                      149.6±27.1      146.5±16.9   0.236
  Blood platelet, 10^3^/mm^3^         242.6±54.1      243.3±56.0   0.923
  IVST, mm                            10.0±1.1        12.±1.2      0.000
  LVEDd, mm                           45.2±4.4        49.1±4.0     0.000
  LVESd, mm                           29.6±4.3        32.3±3.6     0.000
  PWT, mm                             10.1±1.7        11.3±1.3     0.000
  Ejection fraction, %                65.8±5.3        63.5±7.3     0.000
  Left ventricular mass, g            174.5±33.7      240.4±44.4   0.000
  Left ventricular mass index, g/m2   92.3±12.7       128.1±18.5   0.000

Univariate analyses {#sec014}
-------------------

In the whole study population, total bilirubin ([Fig 1](#pone.0125275.g001){ref-type="fig"}) and indirect bilirubin levels ([Fig 2](#pone.0125275.g002){ref-type="fig"}) are negatively associated with LVMI. Sex, smoking status, SBP, glucose, serum creatinine, uric acid, blood urea nitrogen, and RDW are positively associated with LVMI. The association between LVMI and any of other variables is not significant ([Table 2](#pone.0125275.t002){ref-type="table"}).

![Scatter diagram of total bilirubin level between the LVMI.](pone.0125275.g001){#pone.0125275.g001}

![Scatter diagram of indirect bilirubin level between the LVMI.](pone.0125275.g002){#pone.0125275.g002}

10.1371/journal.pone.0125275.t002

###### Correlation coefficients of relation between left ventricular mass index and some parameters.

![](pone.0125275.t002){#pone.0125275.t002g}

  Variables                         Correlation coefficients                     *P*
  --------------------------------- -------------------------------------------- -------
  Age                               -0.055                                       0.307
  Sex                               0.119[\*](#t002fn001){ref-type="table-fn"}   0.027
  Smoking                           0.228[\*](#t002fn001){ref-type="table-fn"}   0.000
  SBP, mmHg                         0.136                                        0.011
  DBP, mmHg                         0.089                                        0.101
  Triglyceride, mmol/dL L           -0.005                                       0.922
  HDL-cholesterol, mmol/dL          -0.057                                       0.293
  LDL- cholesterol, mmol/dL         0.012                                        0.824
  Total cholesterol, mmol/dL        0.004                                        0.944
  Glucose, mmol/dL                  0.142                                        0.008
  eGFR, mL/min/1.73                 -0.111                                       0.039
  Serum creatine, mmol/dL           0.162                                        0.003
  Uric acid, μmol/L                 0.225                                        0.000
  Hs-CRP, mg/dL                     0.064                                        0.246
  Alanine aminotransferase, U/L     -0.024                                       0.656
  Aspartate aminotransferase, U/L   -0.022                                       0.686
  Blood urea nitrogen, mmol/L       0.188                                        0.029
  Total bilibin, μmol/L             -0.245                                       0.000
  Direct bilirubin, μmol/L          -0.012                                       0.624
  Indirect bilirubin, μmol/L        -0.268                                       0.000
  White blood cell, ×10^12^/L       0.032                                        0.556
  Red blood cell, ×10^12^/L         0.060                                        0.267
  Red cell distribution width (%)   0.129                                        0.017
  Hemoglobin,g/L                    -0.053                                       0.325
  Blood platelet, 10^3^/mm^3^       -0.083                                       0.200

\*Spearman correlation coefficient

Multiple linear regression analysis {#sec015}
-----------------------------------

To test whether the relation between total bilirubin level and LVMI was confounded by other factors, we conducted the multiple linear regression by considering a set of potential variables. The results suggest that total bilirubin (B = -0.017, P = 0.008) is negatively associated with LVMI, independent of age, sex, BMI, smoking status, creatinine, fasting glucose, eGFR, hsCRP, TG, HDL-cholesterol, TC, LDL-cholesterol, metabolic, alanine aminotranferease (ALT), aspartate aminotransferase (AST), blood urea nitrogen (BUN), WBC count, Plt count, RBC count, Hb, and Plt count. [Table 3](#pone.0125275.t003){ref-type="table"} shows the results of multiple linear regression performed to assess the independent predictors of LVMI.

10.1371/journal.pone.0125275.t003

###### Stepwise multiple linear regression analysis for the effect of independent variables on left ventricular mass index.
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  Variable          *B*      S.E.    *t*      *P*
  ----------------- -------- ------- -------- -------
  Constant          -1.135   0.443   -2.564   0.011
  Smoking           0.265    0.074   3.578    0.000
  Serum uric acid   0.002    0.001   3.134    0.002
  Total bilirubin   -0.017   0.006   -2.695   0.008
  SBP               0.007    0.003   2.557    0.011

Multiple logistic regression analysis {#sec016}
-------------------------------------

In a stepwise multiple logistic regression model, LVH was defined as the dependent variable and other factors with LVH as covariates. The results show that total bilirubin \[OR = 0.91, 95%CI (confidence interval): 0.85--0.97\] is an independent protective factor of LVH. Other factors including smoking status (OR = 3.14, 95% CI: 1.66--7.00), serum acid (OR = 1.01, 95%CI: 1.00--1.02), and SBP (OR = 1.03, 95%CI: 1.01--1.06) ([Table 4](#pone.0125275.t004){ref-type="table"}).

10.1371/journal.pone.0125275.t004

###### Multivariable logistic regression analysis of prediction of LVH.

![](pone.0125275.t004){#pone.0125275.t004g}

  Variable          *B*      *S*.*E*.   Waldχ^2^   Odds ratio   95% CI       *P*
  ----------------- -------- ---------- ---------- ------------ ------------ -------
  Constant          -8.009   2.333      11.784     \-           \-           0.001
  Smoking           1.227    0.367      11.194     3.14         1.66--7.00   0.001
  Serum uric acid   0.010    0.003      9.178      1.01         1.00--1.02   0.002
  Total bilirubin   -0.090   0.035      6.625      0.91         0.85--0.97   0.010
  SBP               0.032    0.013      6.143      1.03         1.01--1.06   0.013

Discussion {#sec017}
==========

The main findings of the present study are that total serum bilirubin level is negatively associated with LVMI and serves as a protective factor of LVH in hypertensive patients without receiving any drug treatment, regardless of potential confounding factors. The same protective effect of bilirubin on LVH was observed in a hypertensive rat model \[[@pone.0125275.ref022]\]. In a recent report involving 114 consecutive hypertensive patients, bilirubin level is positively related with LVMI and LVH \[[@pone.0125275.ref023]\], which is totally different from our results. Compared with their study, our findings have several strengths that need to be addressed. On one hand, the present study involves a sample size three times larger than theirs (344 vs. 114). Moreover, their logistic regression results show quite a wide CI (1.035--12.846). The small sample size is likely to induce larger sampling error, which reduces the precision of the results. On the other hand, hypertensive patients with diabetes mellitus were excluded from our study. About 10.5% of the study population had diabetes mellitus, and most of them tended to be obesity (BMI: 31.7±5.3), which may have modest effect on our results. Thus, we extended the previous findings using a larger sample size and established that reduction in bilirubin levels may precede the development of LVH in untreated hypertensive patients.

As a major product of heme metabolism in the vessels, serum bilirubin could be poisonous for infants under excessive condition \[[@pone.0125275.ref024]\], but a potential antioxidant material can provide profitable protection against CVDs \[[@pone.0125275.ref025]\]. Actually, many epidemiologic studies demonstrate that higher serum bilirubin level is a protective factor of CVDs. As reported, serum bilirubin level is independently and negatively associated with the occurrence of carotid atherosclerosis in both males and females \[[@pone.0125275.ref026]\]. The causal risk reduction for type 2 diabetes (T2DM) was estimated to be 42%, which was comparable to the observational estimate \[[@pone.0125275.ref027]\]. This result provides strong evidence that the elevated bilirubin level is significantly associated with the reduced risk of T2DM and supports its role as a protective determinant. A prospective large-scale and community-based cohort with 8593 Korean patients shows that lower bilirubin level is an risk factor of coronary artery disease \[adjusted hazard ratio:1.89 \[[@pone.0125275.ref028]\]. Our results support the current opinion. The exact mechanism about the association between serum bilirubin level and LVH remains unclear, but there are several possible reasons. First, bilirubin is an antioxidant, which has been confirmed in vitro and in vivo \[[@pone.0125275.ref029], [@pone.0125275.ref030]\]. Human trials also suggest that bilirubin level is positively related with the total antioxidant capacity \[[@pone.0125275.ref031]\]. It is generally suggested that oxidative reactions are involved in the pathophysiology of CVDs \[[@pone.0125275.ref032]\]. Bilirubin can suppress the oxidative modification of LDL-lipoprotein, an important part of the development of atherosclerosis. Second, serum bilirubin may be associated with LVH through the close relation with regular risk factors. It is suggested that high bilirubin levels are negatively associated with the presence of obesity, smoking status, diabetes mellitus, hypertension and metabolic syndrome. Finally, the anti-inflammatory function of bilirubin can partly explain why bilirubin level is lower in the LVH group. Animal experiments prove that the intake of bilirubin can affect the expressions of cell adhesion molecules \[[@pone.0125275.ref033]\]. Besides, an epidemiological study also reveals the inverse relation between bilirubin and hs-CRP \[[@pone.0125275.ref034]\]. Nevertheless, further studies are needed.

The present study has several limitations. First and most importantly, the nature of cross-sectional design does not allow us to confirm the cause-and-effect relation. Actually, the serum bilirubin level is very valuable as a reference in clinic, no matter the lower serum bilirubin is a cause or effect of LVH. After all, the serum bilirubin level could be thought as a relative index to LVH. Second, some inflammation markers (interleukin-6 and -10) were not reported. Bilirubin without other clinical index may not provide enough information for clinicians. Third, it should be noted that our findings are based on the selected Asian population with moderate primary hypertension. Patients with CKD or cardiovascular diseases were excluded from this study. Therefore, the extrapolation to other populations will be limited. Nevertheless, this point makes our results independent from some confounders. Finally, although our results prove an inverse association different from previous research, the specific mechanism cannot be illustrated clearly. Therefore, further studies regarding the role of serum bilirubin on the development of LVH are needed.

In conclusion, total serum bilirubin level is inversely associated with the development of LVH in the untreated hypertensive patients after adjustment of some potential confounders. Thus, as a routine quick laboratory examination index, serum bilirubin level may be treated as a novel marker for evaluation of target organ damage risk (especially LVH) in hypertensive patients. Subsequent studies should focus on the exact biological mechanism.
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